8 SUMMIT also demonstrated significant improvements in patient-reported outcomes: at 52 weeks, tirzepatide increased KCCQ-CSS, with a between-group mean difference of 6.9 points, and increased 6-minute walk distance, with a between-group mean difference of 18.3 m
Always check with your provider when considering multiple treatments to ensure the best outcomes for your health goals.
Neurology International (2022) Bremelanotide for Female HSDD (mechanism and usage) Safarinejad, M.R., et al
Discussion GSH has been linked to nearly every cellular process in the body 71,72
Sang Kwon, Jong Eun Yeon, Soon Koo Baik Journal of Gastroenterology and Hepatology .2026
A Phase 2 randomised controlled trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023) reported that participants receiving higher doses of retatrutide (up to 12 mg) achieved mean body weight reductions of approximately 1724% over 48 weeks